<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although less than 1% of patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) develop the catastrophic variant, its potentially lethal outcome emphasizes its importance in clinical medicine today </plain></SENT>
<SENT sid="1" pm="."><plain>However, the rarity of this variant makes it extraordinarily difficult to study in any systematic way </plain></SENT>
<SENT sid="2" pm="."><plain>In order to put together <z:hpo ids='HP_0000001'>all</z:hpo> of the published case reports as well as the new diagnosed cases from <z:hpo ids='HP_0000001'>all</z:hpo> over the world, an international registry of patients with catastrophic APS (CAPS Registry) was created in 2000 by the European Forum on <z:hpo ids='HP_0003613'>Antiphospholipid Antibodies</z:hpo> (see http://www.med.ub.es/MIMMUN/FORUM/CAPS.HTM) </plain></SENT>
<SENT sid="3" pm="."><plain>Currently, it documents the entire clinical, laboratory and therapeutic data of more than 300 patients whose data has been fully registered </plain></SENT>
</text></document>